Sleep Disorders Trial, Recruiting NCT06157840 Sponsor: Medical University of South Carolina Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT06157840
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have not experienced withdrawal symptoms in the past 2 weeks
  • People who are currently stabilised on buprenorphine, either having started it within the past 3 months or having had their dose adjusted within the past 3 months (for example, reducing the dose with a goal of moving to a different medication)
  • People who are currently experiencing significant sleep disturbances, as measured by a standard sleep quality assessment (confirm with trial site)
  • People who are able to read and understand English
  • People who own an Android or iOS smartphone
  • People who are at least 18 years of age

Who may not be able to join:

  • People who are currently experiencing symptoms of psychosis
  • People who are currently having active thoughts of suicide
  • People with severe visual impairment
  • People who are currently using benzodiazepines (a type of sedative or anti-anxiety medication)
  • People who currently have a severe substance use disorder involving a substance other than opioids, meaning they meet more than 5 diagnostic criteria for another substance use disorder (confirm with trial site)
  • People who are currently pregnant or in the period shortly after giving birth

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Allison K Wilkerson, Ph.D., Medical University of South Carolina

Phone: 843-792-4636

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
25 August 2025
Est. completion
15 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Enrollment feasibility/acceptability benchmark of at least 30 persons completing entire study period - Enrollment and retention percentages; Protocol adherence feasibility/acceptability benchmarks of participants completing modules and sleep diaries each week - Engagement; mHealth App Usability Questionnaire

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov